IMMX News and Press, Immix Biopharma Inc. From 11/06/23

2023-11-06 15:35:37 ET More on Immix Biopharma, Inc. Immix Biopharma: A Mid-To-Late Stage CAR-T Biotech Quietly Gaining Momentum Immix gains FDA orphan drug status for CAR-T therapy Immix Biopharma director acquires $200K worth of shares Seeking Alpha’...

100% overall response rate observed in relapsed/refractory AL Amyloidosis patients with median 6 lines of prior therapy Updated results will be communicated at the presentation time December 10, 2023 LOS ANGELES, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (Nasdaq:IMMX) (&#x...

95% overall response rate observed in relapsed/refractory multiple myeloma patients not previously treated with BCMA-targeted therapy 98% overall response rate observed in relapsed/refractory multiple myeloma patients without extra-medullary disease Updated results will be communicated at...

2023-10-27 08:23:45 ET Losers: PTC Therapeutics PTCT -23% after Q3 earning release . Sanofi SNY -17% after Q3 earning release . Enphase Energy ENPH -17% after Q3 earning release . Jaguar Global Growth Corp I ( JGGC ) -13%. NatWest Group ...

Dr. Liedtke joins Nexcella Scientific Advisory Board with decades of hematology/oncology clinical trial experience at Stanford University Medical Center Dr. Liedtke is a recognized thought leader in CAR-T cell therapy and designing clinical trials in AL Amyloidosis and Multiple Myeloma ...

Successful completion supports expansion of its ongoing NEXICART-1 (NCT04720313) NXC-201 CAR-T clinical trial to the U.S. NXC-201 is manufactured at our state-of-the-art cellular immunotherapy manufacturing facility in California LOS ANGELES, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Immix Biop...

2023-10-06 11:25:33 ET Summary Welcome to another installment of our monthly Rare Buy article where we highlight September investment picks you may have missed. As you know some Seeking Alpha analysts are more discerning by nature. Others are finding compelling ideas hard to come ...

2023-10-05 10:00:20 ET More on Health Care Select Sector SPDR BofA Securities: Which small cap non-earner stocks to avoid Citi turns cautious on pharmaceuticals and biotech For further details see: Orchard Therapeutics, Longeveron among healthcare movers

Shares of Immix Biopharma, Inc. (NASDAQ: IMMX) traded at a new 52-week high today and are currently trading at $4.6. So far today, approximately 104.97k shares have been exchanged, as compared to an average 30-day volume of 318.21k shares. Immix Biopharma, Inc., a clinical-stage biopharmaceut...

100% (9/9) overall response rate and 67% (6/9) complete response rate (MRD 10 -5 ) observed in heavily pre-treated patients with daratumumab relapsed/refractory AL Amyloidosis as of the September 20, 2023 data cutoff 100% (4/4) overall response rate and 75% (3/4) complete response rate ob...